Drugs / NVL-330
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06521554 | Jul 2024 → Jan 2027 expected | metastatic neoplasm | Nuvalent Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVL-330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06521554 ↗ |
| Action | Inhibit | “Selective Tyrosine Kinase Inhibitor NVL-330” NCT06521554 ↗ |
| Route | Oral | “NVL-330 oral daily dosing” NCT06521554 ↗ |